Try the modernized ClinicalTrials.gov beta website. Learn more about the modernization effort.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Are the Patients Having Pets at Greater Risk of Carrying Multidrug Resistance Bacteriae? (BRANITRANS)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03352804
Recruitment Status : Recruiting
First Posted : November 24, 2017
Last Update Posted : December 16, 2019
Sponsor:
Information provided by (Responsible Party):
CHU de Reims

Study Description
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:

Introduction : The multidrug resistance (MDR) Bacteriae are growing and are a public health problem. The known risk factors to be expanding of MDR Bacteriae are: taken antibiotics, hospitalization, journey in a country at risk. Other risk factors are emitted in hypothesis as the presence of pets.

Aim : The primary objective is to study the association between the presence of a pet and the presence of a MDR bacteria. Methods : Cross sectional study will be performed in Reims University hospital in internal medicine ward.


Condition or disease Intervention/treatment
Multidrug Resistance Other: Screening of MDR Bacteriae

Detailed Description:

Introduction : The multidrug resistance (MDR) Bacteriae are growing and are a public health problem. The known risk factors to be expanding of MDR Bacteriae are: taken antibiotics, hospitalization, journey in a country at risk. Other risk factors are emitted in hypothesis as the presence of pets.

Aim : The primary objective is to study the association between the presence of a pet and the presence of a MDR bacteria.

Methods : Cross sectional study will be performed in Reims University hospital in internal medicine ward. Within the framework of the management of patients in internal medicine ward, all the hospitalized patients have systematically a screening of MDR Bacteriae. A questionnaire will be put handed to all the patients during their hospitalization as soon as they will be able to answer it. They will be informed about the objectives of the study. If the patient agrees to participate in the study, the questionnaire will be filled by every patient. It includes essentially closed questions and some open questions. A descriptive analysis will be performed. Bivariate analysis will be performed to investigate the relation between the presence of a pet and the presence of a MDR bacteria and clinical variables Multivariate logistic regression will be performed to investigate the factors independently related to the presence of a MDR bacteria.

Study Design
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Observational
Estimated Enrollment : 900 participants
Observational Model: Case-Crossover
Time Perspective: Cross-Sectional
Official Title: Are the Patients Having Pets at Greater Risk of Carrying Multidrug Resistance Bacteriae?
Actual Study Start Date : June 12, 2017
Estimated Primary Completion Date : June 11, 2024
Estimated Study Completion Date : January 2025
Groups and Cohorts
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Group/Cohort Intervention/treatment
Patients hospitalized in internal medicine ward
Patients included are patients hospitalized in internal medicine ward.
 Other: Screening of MDR Bacteriae
questionnaire will be filled by every patient


Outcome Measures
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. Association between the presence of a pet and the presence of a MDR bacteria [ Time Frame: Day0 ]

Eligibility Criteria
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Patients hospitalized in internal medicine ward of Reims University hospital
Criteria

Inclusion Criteria:

  • Patients who were screened for MDR bacteria
  • Patients who accepted to participate in the study
  • >18yo

exclusion criteria :

  • Patient hospitalized before admission in our ward and having acquired a MDR bacteria in the course of care.
  • Patients coming from nursing home or institutionalized patients
  • Patient who cannot communicated
Contacts and Locations
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03352804


Contacts
Layout table for location contacts
Contact: Firouze BANI SADR 3.26.78.71.86 ext 33 fbanisadr@chu-reims.fr

Locations
Layout table for location information
France
Chu Reims Recruiting
Reims, France, 51092
Contact: Damien JOLLY    326788472 ext 33    djolly@chu-reims.fr   
Sponsors and Collaborators
CHU de Reims
More Information
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information
Layout table for additonal information
Responsible Party: CHU de Reims
ClinicalTrials.gov Identifier: NCT03352804    
Other Study ID Numbers: PO17041
First Posted: November 24, 2017    Key Record Dates
Last Update Posted: December 16, 2019
Last Verified: December 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No